Navigation Links
Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer

peutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus (RSV) infection. RSV infects nearly every child at least once by the age of two and accounts for more than 100,000 hospitalizations annually in the U.S. pediatric population. RSV infection also poses a great risk to the elderly and other adults with compromised immune systems. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach, Germany. For more information, visit www.alnylam.com.

Alnylam Forward-Looking Statements

Various statements in this release concerning our future expectations, plans, and prospects, including statements concerning the timing of filing an IND for ALN-VSP01, statements concerning use of RNAi therapeutics for the treatment of liver and other cancers, statements concerning use of siRNAs to achieve therapeutic silencing of genes and statements concerning effective delivery of siRNAs, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. ... provide a corporate update and report second quarter 2014 ... on Friday, August 1, 2014. That same day, Arena ... a.m. Eastern Time (5:30 a.m. Pacific Time). ... 877.643.7155 for domestic callers and 914.495.8552 for international callers. ...
(Date:7/24/2014)... Kan. , July 24, 2014  Parnell ... two compounds that will be added to Parnell,s ... Australian-based CIMTECH Pty Ltd, a biotechnology company. The ... 122 have shown promise in bone regeneration and ... to develop the compounds for the veterinary market ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Reportlinker.com announces that a new market research ... Levosimendan - Comprehensive patent search ... unnecessary risk with the industry benchmark in comprehensive ... regularly updated, professional patent search performed by our ...
... 20, 2011 Sagent Pharmaceuticals (Nasdaq: SGNT ) ...  The size of the offering has been increased from the ... of common stock at a price to the public of ... on The NASDAQ Global Market on April 20, 2011 under ...
Cached Medicine Technology:Reportlinker Adds Levosimendan - Comprehensive patent search 2Reportlinker Adds Levosimendan - Comprehensive patent search 3Reportlinker Adds Levosimendan - Comprehensive patent search 4Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering 2
(Date:7/28/2014)... (PRWEB) July 28, 2014 ... "McDonald’s continues to market to a disadvantaged ... Hispanic. They use proven, often offensive, ethnically-slanted ... of people." ('The Tainted Burger." Amazon: ... with Anna Lappe', author and activist who ...
(Date:7/27/2014)... (PRWEB) July 28, 2014 Zensah®, the leader ... offering to include a wrist support . The wrist ... the wrist area. , Lateral and Medial Epicondylitis, more commonly ... condition in which there is inflammation of the tendons attached ... unrelated to wrist pain, the muscles that work the wrist ...
(Date:7/27/2014)... a reliable online supplier of women’s special occasion outfits, has ... on its website. Now, all these charming gowns are provided ... are pleased to add the new fabulous prom dress collection ... who are in need of fashionable special occasion outfits. Each ... our clients will love them. Ladies, just visit our online ...
(Date:7/27/2014)... Bags underneath the eyes is one condition that both ... a range of new products now available from Internet retailers. ... serum review that is now posted for adults to access ... with baggy eyes and how the natural ingredients in some ... also provides a detailed overview of the creams and oils ...
(Date:7/27/2014)... virus (HEV) transmission by blood components indicates that about ... their plasma. The findings, published in The Lancet ... red cells, platelets, and fresh frozen plasma) are likely ... The study retrospectively screened 225 000 individual blood donations ... Sept, 2013 for HEV RNA. 79 donors were found ...
Breaking Medicine News(10 mins):Health News:The Tainted Burger- McDonalds's Franchise Owner's Tale by Author Michael B. Potts Says McDonald's Disproportionately Markets to Minorities--Tedx Video Supports Claim 2Health News:Zensah® Releases New Wrist Support 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2
... Feb. 3 The Ensign Group, Inc. (Nasdaq: ... into Colorado by acquiring four long-term care facilities in ... a 35-bed skilled nursing facility in Littleton, Arvada Nursing ... Temple Center, a 128-bed skilled nursing facility in Englewood, ...
... DEL MAR, Calif., Feb. 3 Plastic & ... the field, published the remarkable safety record of ... killer blood clots to the lungs (pulmonary embolism ... over the past 16 years! This series included ...
... for online vacuum cleaner reviews. , ... Boise, Idaho (PRWEB) February 3, ... will collaborate with The Carpet and Rug Institute (CRI) to ... "Seal of Approval" designation. , , , , ,The new series seeks ...
... web based user self service & identity management software solution that allows ... accounts easily and securely via a web browser, and ends the need ... ... 3, 2009 -- SysOp Tools, Inc. announced that Password Reset PRO, a ...
... Feb. 3 Beneficiaries enrolled in Medicare Part D ... as the "doughnut hole" were much less likely to ... according to a University of Pittsburgh Graduate School of ... 3 online issue of Health Affairs , raise ...
... in the February issue of the Journal of the ... to 20 minutes with simple surgical exercises prior to an ... skills in surgeons of all experience levels. The researchers found ... surgeons, alertness to a higher level for surgical procedures and ...
Cached Medicine News:Health News:The Ensign Group Expands into Colorado 2Health News:Cosmetic Surgery - No Killer Blood Clots to the Lungs Sans GA, PK Anesthesia Can Save the Day 2Health News:The Housekeeping Channel (HC) and The Carpet and Rug Institute (CRI) Partner on Vacuum Cleaner Reviews 2Health News:The Housekeeping Channel (HC) and The Carpet and Rug Institute (CRI) Partner on Vacuum Cleaner Reviews 3Health News:New Web-Based User Self Service & Identity Management Software for Active Directory takes Security, User Convenience to a Whole New Level 2Health News:New Web-Based User Self Service & Identity Management Software for Active Directory takes Security, User Convenience to a Whole New Level 3Health News:Seniors in Medicare's doughnut hole decrease use of meds 2Health News:Journal of American College of Surgeons study finds warm-up helps surgeons improve performance 2
... the most advanced visual electrodiagnostic system ... of retinal and optic nerve function. ... drives this powerful computer-controlled instrument. With ... pattern stimulation, rapid Ganzfeld flash rate ...
... The Universal Biomedical Amplifier (UBA-4204) ... true DC signal amplification and ... commonly seen amplifier problems of ... saturation. These features make the ...
The STALIF stand-alone anterior lumbar fusion cage is the latest product development from Surgicraft. STALIF is the natural evolution of the Hartshill Horseshoe, which has over 10 years clinical suc...
... PACHETTE 3 will enable eye care professionals ... utilizing improved ultrasound technology. The PACHETT 3 ... algorithm used in all the DGH pachymeters ... DGH Model 555 PACHETTE 3 is capable ...
Medicine Products: